Prescription Products
Uftoral capsules
Composition: Combination of tegafur 100mg and
uracil 224mg per capsule.
Presentation: Capsules.
Storage and stability: Do not store above
25C.
Action: Cytotoxic antimetabolite.
Indications: First-line treatment of metastatic colorectal cancer
in combination with calcium folinate.
Contraindications: Hypersensitivity to 5-fluorouracil,
tegafur, uracil or excipients; pregnant or attempting to become pregnant;
breast feeding; adolescents, children or infants; severe hepatic impairment;
evidence of bone marrow suppression from previous radiotherapy or antineoplastic
agents; deficiency of hepatic CYP2A6.
Dosage and administration: A dose of 300mg/m2/day
of tegafur and 672mg/m2/day should be taken at the same time
as calcium folinate 90mg/day, in three divided doses (preferably every
eight hours). Doses should be taken at least one hour before before or
one hour after meals for 28 days. Subsequent cycles should be started
after seven days without Uftoral and calcium folinate. See SPC for number
of capsules per body surface area, daily dosing schedule and dose modification
guidelines for managing toxicity.
Adolescents, children and infants, should
not be used. Safety and efficacy has not been established.
Elderly, use with caution.
Renal impairment, use with caution. Monitor
for emergent toxicities.
Hepatic impairment, use with caution.
Overdosage: Manifestations of overdose might
include nausea, vomiting, diarrhoea, gastrointestinal ulceration, bleeding
and bone marrow suppression. No specific antidote is available, but supportive
care should be provided.
Precautions: Use with care in patients who
are known or suspected to have a dihydropyrimidine dehydrogenase deficiency.
Use with caution in patients with signs and symptoms of bowel obstruction.
Drug interactions: Uftoral should not be
administered with any product that acts by inhibiting dihydropyrimidine
dehydrogenase, because of the potential for increased toxicity. Marked
elevations in prothrombin time (PT) or international normalised ratio
(INR) have been reported in patients stabilised on warfarin therapy.
Side effects: Very common (>=10 per cent)
undesirable effects include diarrhoea, nausea, stomatitis, anorexia, vomiting,
abdominal pain and asthenia. Common (>=1 per cent, <10 per cent)
undesirable effects include constipation, flatulence, dyspepsia, mucositis,
dry mouth, eructation, anorexia, intestinal obstruction, fever, headache,
malaise, chills, pain, moniliasis, dehydration, cachexia, taste perversion,
taste loss, somnolence, dizziness, insomnia, depression, paresthesia,
confusion, lacrimation and conjunctivitis, peripheral oedema, deep thrombo-phlebitis,
dyspnoea, increased coughing, pharyngitis, alopecia, rash, exfoliative
dermatitis, skin discoloration, pruritus, photosensitivity, sweating,
dry skin, nail disorder, myalgia, back pain and arthralgia. See SPC for
uncommon undesirable effects and for hepatobiliary and haematological
laboratory abnormalities.
Net price: 21 £119.91, 28 £159.88,
35 £199.88, 42 £239.82.
Supplier: Bristol-Myers Squibb Pharmaceuticals,
Bristol-Myers Squibb House, 141-149 Staines Road, Hounslow, Middlesex
TW3 3JA. Tel 020 8754 3740, fax 020 8754 3677.
Legal class: POM.
Femoston 1/10 tablets
The
licensed indications for Solvay Healthcare's Femoston 1/10 (estradiol
1mg, dydrogesterone 10mg) tablets have been extended. This strength of
Femoston, along side Femoston 2/10 and Femoston 2/20, is now additionally
licensed for the prevention of osteoporosis in women at risk of developing
fractures.
Tritace capsules
Aventis
Pharma is launching Tritace (ramipril) 2.5mg capsules, pack size 7 (net
price, £1.88).
Generics (UK) products
Generics
(UK) has launched co-codamol 8/500mg tablets (net price, 100 £1.65) and
trazodone capsules (net price, 50mg 84 £17.31, 100mg 56 £20.38).
Back to Top
|
